CKD-828 Telmisartan Non-Responder Trial

Phase 3

Completed

• Conditions: Hypertension
• Interventions: Drug: Telmisartan 80mg; Drug: CKD-828 40/2.5mg; Drug: CKD-828 40/5mg

• Registration Number: NCT01426100
• Lead Sponsor: Chong Kun Dang Pharmaceutical

Brief Summary

The aim of the present study is to evaluate the efficacy and safety of two dose combination of Telmisartan/S-Amlodipine (40/2.5mg and 40/5mg) compared with telmisartan monotherapy (80mg) in hypertensive patients inadequately controlled by telmisartan monotherapy.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-08
• Study First Submitted: 2011-08-30
• Study First Submitted QC: 2011-08-30
• Study First Posted: 2011-08-31
• Primary Completion: 2012-05
• Study Completion: 2012-08
• Status Verified: 2012-09
• Last Update Submitted: 2012-09-11
• Last Update Posted: 2012-09-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 183

Inclusion Criteria

• age 18 years or older
• diagnosis of essential hypertension and blood pressure not adequately controlled(inadequate control defined as seated diastolic blood pressure(DBP)>= 90mmHg if on existing antihypertensive treatment of seated DBP >= 100mmHg if treatment naive)
• failure to respond to four weeks treatment with telmisartan 40mg(failure to respond defined as seated DBP >= 90mmHg)
• willing and able to provide written informed consent

Read More

Exclusion Criteria

• mean seated DBP >= 120mmHg and/or mean seated SBP >= 200mmHg during run-in treatment or mean seated DBP >= 120mmHg and/or mean seated SBP >= 180mmHg at the randomization visit
• known or suspected secondary hypertension(ex. aortic coarctation, Primary hyperaldosteronism, renal artery stenosis, pheochromocytoma)
• has severe heart disease(Heart failure NYHA functional class 3, 4), unstable angina or myocardial infarction, arrhythmia within the past three months
• has cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6 months
• Type I Diabetes Mellitus, Type II Diabetes Mellitus with poor glucose control as defined by fasting glucosylated hemoglobin(HbA1c) > 8%
• nown severe or malignant retinopathy
• hepatic or renal dysfunction as defined by the following laboratory parameters: AST/ALT > UNL X 2, serum creatinine > UNL X 1.5
• acute or chronic inflammatory status need to treatment
• need to additional antihypertensive drugs during the study
• need to concomitant medications known to affect blood pressure during the study
• history of angioedema related to ACE inhibitors or Angiotensin II Receptor Blockers
• known hypersensitivity related to either study drug
• history of drug or alcohol dependency within 6 months
• any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of investigational products(ex. gastrointestinal tract surgery such as gastrectomy, gastroenterostomy or bypass, active inflammatory bowel syndrome within 12 months prior to screening, gastric ulcers need to treatment, gastrointestinal/rectal bleeding, impaired pancreatic function such as pancreatitis, obstructions of the urinary tract or difficulty in voiding
• administration of other study drugs within 30 days prior to randomization
• premenopausal women(last menstruation < 1year) not using adequate contraception, pregnant or breast-feeding
• history of malignancy including leukemia and lymphoma within the past 5 years
• in investigator's judgment

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Telmisartan 80mg	Telmisartan 80mg	-
CKD-828 40/2.5mg	CKD-828 40/2.5mg	-
CKD-828 40/5mg	CKD-828 40/5mg	-

Primary Outcome Measures

Name	Time	Method
Mean Sitting Diastolic Blood Pressure (MSDBP)	After 8 weeks of treatment

Secondary Outcome Measures

Name	Time	Method
Mean Sitting Diastolic Blood Pressure (MSDBP)	After 4 weeks of treatment
Mean Sitting Systolic Blood Pressure (MSSBP)	After 4 weeks and 8 weeks of treatment
Response rate	After 4 weeks and 8 weeks of treatment	Reduction of SBP ≥ 20mmHg, DBP ≥ 10mmHg
Control rate	After 4 weeks and 8 weeks of treatment	Reduction SBP \< 140mmHg, DBP \< 90mmHg

Trial Locations

Locations (18)

Chonbuk National University Hospital; 🇰🇷 Jeonju, Korea, Republic of

Ewha Womans University Hospital; 🇰🇷 Seoul, Korea, Republic of

Daegu Catholic University Medical Center; 🇰🇷 Daegu, Korea, Republic of

Severance Hospital; 🇰🇷 Seoul, Korea, Republic of

DonGuk University Ilsan Hospital; 🇰🇷 Goyang, Korea, Republic of

Keimyung University Dongsan Medical Center; 🇰🇷 Daegu, Korea, Republic of

Kandong Sacred Heart Hospital; 🇰🇷 Anyang, Korea, Republic of

Bundang Cha Medical Center; 🇰🇷 Seoul, Korea, Republic of

National Health Insurance Corporation Ilsan Hospital; 🇰🇷 Goyang, Korea, Republic of

Gachon University Gil Medical Center; 🇰🇷 Inchon, Korea, Republic of

Seoul National University Bundang Hospital; 🇰🇷 Seongnam, Korea, Republic of

Kyung Hee University Medical Center; 🇰🇷 Seoul, Korea, Republic of

Inje University Ilsan Paik Hospital; 🇰🇷 Seoul, Korea, Republic of

Korea University Guro Hospital; 🇰🇷 Seoul, Korea, Republic of

Gangnam Severance Hospital; 🇰🇷 Seoul, Korea, Republic of

St. Paul's Hospital, The catholic University of Korea; 🇰🇷 Seoul, Korea, Republic of

Soon Chun Hyang University Hospital; 🇰🇷 Seoul, Korea, Republic of

Ajou University Hospital; 🇰🇷 Suwon, Korea, Republic of